Mumbai, India – March 4, 2026 – Qure.ai, a global leader in AI-powered radiology, today celebrated FDA clearance for its qXR-Detect chest X-ray AI solution, completing a comprehensive suite now spanning 26 clinical indications. This pivotal milestone supercharges TB and lung disease screenings worldwide, positioning Qure.ai to capture a $15B+ AI diagnostics market exploding at 35% CAGR through 2030.
qXR-Detect delivers 95%+ sensitivity for detecting tuberculosis, pneumonia, and lung nodules—reducing diagnosis time by 50% and enabling frontline detection in resource-limited settings. Building on 50M+ global scans analyzed, the expanded suite now covers cardiomegaly, fractures, and effusions, driving 30% workflow efficiency gains for radiologists overburdened by 20% annual imaging volume growth.
“This clearance marks Qure.ai’s dominance in chest imaging AI, empowering 1B+ annual X-rays to prioritize high-risk cases and avert 2M preventable TB deaths yearly,” said Prashant Warier, CEO of Qure.ai. “Our zero-shot learning engine ensures seamless scalability across devices, delivering ROI in months—not years.”
In parallel, Brainlab announced a strategic partnership with Precision NeuroMed to advance AI-driven treatment planning for glioblastoma, the deadliest brain cancer with 15-month median survival. This collaboration integrates Brainlab’s Elements platform with Precision NeuroMed’s AI models, optimizing radiotherapy contours by 40% and targeting a $5B neuro-oncology segment ripe for precision disruption.
Industry leaders forecast agentic AI—autonomous agents handling end-to-end workflows—will redefine 2026 clinical operations, slashing administrative burdens by 50% and elevating patient outcomes. Qure.ai’s qXR suite and Brainlab’s neuro-AI exemplify this shift, unlocking $100B+ in global value through predictive triage, real-time decision support, and integrated care pathways.
Qure.ai Snapshot
Trusted by Mayo Clinic, GE Healthcare, and 200+ institutions across 90 countries, Qure.ai’s FDA-cleared portfolio processes 10M+ studies annually, with partnerships fueling 100% YoY revenue growth.
By